Hematopoietic SCT in Europe 2013: Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

J. R. Passweg, H. Baldomero, P. Bader, C. Bonini, S. Cesaro, P. Dreger, R. F. Duarte, C. Dufour, J. H F Falkenburg, D. Farge-Bancel, A. Gennery, N. Kröger, F. Lanza, A. Nagler, A. Sureda, M. Mohty

Research output: Contribution to journalArticle

Abstract

A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%; 91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.

Original languageEnglish
Pages (from-to)476-482
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number4
DOIs
Publication statusPublished - Apr 4 2015

Fingerprint

Unrelated Donors
Fetal Blood
Tissue Donors
Transplants
Siblings
Blood Donors
Neoplasms
Leukemia
Growth

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hematopoietic SCT in Europe 2013 : Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. / Passweg, J. R.; Baldomero, H.; Bader, P.; Bonini, C.; Cesaro, S.; Dreger, P.; Duarte, R. F.; Dufour, C.; Falkenburg, J. H F; Farge-Bancel, D.; Gennery, A.; Kröger, N.; Lanza, F.; Nagler, A.; Sureda, A.; Mohty, M.

In: Bone Marrow Transplantation, Vol. 50, No. 4, 04.04.2015, p. 476-482.

Research output: Contribution to journalArticle

Passweg, JR, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, RF, Dufour, C, Falkenburg, JHF, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Nagler, A, Sureda, A & Mohty, M 2015, 'Hematopoietic SCT in Europe 2013: Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants', Bone Marrow Transplantation, vol. 50, no. 4, pp. 476-482. https://doi.org/10.1038/bmt.2014.312
Passweg, J. R. ; Baldomero, H. ; Bader, P. ; Bonini, C. ; Cesaro, S. ; Dreger, P. ; Duarte, R. F. ; Dufour, C. ; Falkenburg, J. H F ; Farge-Bancel, D. ; Gennery, A. ; Kröger, N. ; Lanza, F. ; Nagler, A. ; Sureda, A. ; Mohty, M. / Hematopoietic SCT in Europe 2013 : Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 4. pp. 476-482.
@article{bee6100a765d4413abfcc94ecf3bea01,
title = "Hematopoietic SCT in Europe 2013: Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants",
abstract = "A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43{\%}) and 19 859 autologous (57{\%})) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32{\%}; 96{\%} allogeneic); lymphoid neoplasias, 19 958 (57{\%}; 11{\%} allogeneic); solid tumors, 1543 (4{\%}; 4{\%} allogeneic); and nonmalignant disorders, 1975 (6{\%}; 91{\%} allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96{\%} in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.",
author = "Passweg, {J. R.} and H. Baldomero and P. Bader and C. Bonini and S. Cesaro and P. Dreger and Duarte, {R. F.} and C. Dufour and Falkenburg, {J. H F} and D. Farge-Bancel and A. Gennery and N. Kr{\"o}ger and F. Lanza and A. Nagler and A. Sureda and M. Mohty",
year = "2015",
month = "4",
day = "4",
doi = "10.1038/bmt.2014.312",
language = "English",
volume = "50",
pages = "476--482",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Hematopoietic SCT in Europe 2013

T2 - Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

AU - Passweg, J. R.

AU - Baldomero, H.

AU - Bader, P.

AU - Bonini, C.

AU - Cesaro, S.

AU - Dreger, P.

AU - Duarte, R. F.

AU - Dufour, C.

AU - Falkenburg, J. H F

AU - Farge-Bancel, D.

AU - Gennery, A.

AU - Kröger, N.

AU - Lanza, F.

AU - Nagler, A.

AU - Sureda, A.

AU - Mohty, M.

PY - 2015/4/4

Y1 - 2015/4/4

N2 - A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%; 91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.

AB - A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%; 91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.

UR - http://www.scopus.com/inward/record.url?scp=84926420237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926420237&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.312

DO - 10.1038/bmt.2014.312

M3 - Article

C2 - 25642761

AN - SCOPUS:84926420237

VL - 50

SP - 476

EP - 482

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -